SCHEMBL9955877

SCHEMBL9955877

Cc1cc(-c2ccc(C)nc2C=O)on1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
S100A4 P26447 1/20 0.39
BRD4 O60885 1/20 0.38
EGLN2 Q96KS0 1/20 0.36
POLB P06746 1/20 0.35
MAOA P21397 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP19A1 P11511 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
PRKAB2 O43741 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10262356 0.78 KDM4E (0.46) KDM4EUSP2ALDH1A1TSHRKMT2A
SCHEMBL607939 0.77 OPRK1 (0.43) KDM4EALDH1A1TSHRKMT2AS100A4
SCHEMBL9955618 0.73 ALDH1A1 (0.57) KDM4EUSP2ALDH1A1TSHRKMT2A
SCHEMBL2487359 0.72 ALDH1A1 (0.56) KDM4EUSP2ALDH1A1TSHRKMT2A
Lithium Ion SCHEMBL2487357 0.71 KDM4E (0.48) KDM4EUSP2ALDH1A1TSHRKMT2A
SCHEMBL2473885 0.70 KDM4E (0.47) KDM4EUSP2ALDH1A1TSHRKMT2A
SCHEMBL9953968 0.69 S100A4 (0.39) S100A4CYP1A2MAPT
SCHEMBL4980980 0.69 TP53 (0.41) KMT2AMEN1TP53MAPTNPC1
SCHEMBL9955665 0.68 S100A4 (0.38) ALDH1A1S100A4BRD4TP53HCRTR2
SCHEMBL29912137 0.68 S100A4 (0.38) ALDH1A1S100A4BRD4TP53HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012085857-A1 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES ACTELION PHARMACEUTICALS LTD (CH) 2012-06-28 WO disclosed
US-20110257198-A1 PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2011-10-20 US disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257198-A1 PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, VIPR2 KDM4E 1459/4885USP2 3775/4885ALDH1A1 1507/4885
US-20100144760-A1 NOVEL COMPOUNDS HTR3B, HTR1B, HTR2B KDM4E 1224/4885USP2 4322/4885ALDH1A1 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.